Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
Japan’s Ministry of Health, Labor and Welfare (MHLW) has announced a list of 14 companies that will be eligible for grants under its emergency subsidy project for stable drug supply systems. The roster includes the manufacturers of major antitussives and…
To read the full story
Related Article
- FY2023 Extra Budget Clears Diet, 1.4 Billion Yen to Boost Drug Production
December 1, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
REGULATORY
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…